Gapping down
In reaction to disappointing earnings/guidance: AMKR -17.5%, BIDU -12.6%, CKEC -11.7%, COMM -5.7%, AVB -5.5%, AUDC -1.8%, CR -1.7%, TACO -1.4%, PRAH -1.4%, ALSN -1.3%, DD -1.2%
Other news: IMMU -45.6% (Belgium's UCB Phase 3 clinical trial program for Epratuzumab did not meet primary endpoint; Epratuzumab was licensed from IMMU), AMDA -30.3% (announced the FDA has requested co provide 24-month clinical performance data for pending 510(k) submission for the Valeo C Interbody with CsC Osteo-Conductive Scaffolding; co also provided in-line Q2 rev guidance), CARA -6.7% (commenced an underwritten public offering of shares of its common stock of up to $65 million), EGLT -5.4% (to offer and sell shares of its common stock in an underwritten public offering; size not disclosed), NYMX -1.6% (following 100% move higher yesterday), ADPT -1.5% (announces an offering of 2.75 mln shares of common stock; ~1.91 mln shares to be sold by co, ~843K shares to be sold by Sterling Partners shareholder group), YOKU -0.8% (following BIDU results), SINA -0.5% (following BIDU results)
Analyst comments: YELP -2.9% (downgraded to Hold from Buy at Deutsche Bank
)
In reaction to disappointing earnings/guidance: AMKR -17.5%, BIDU -12.6%, CKEC -11.7%, COMM -5.7%, AVB -5.5%, AUDC -1.8%, CR -1.7%, TACO -1.4%, PRAH -1.4%, ALSN -1.3%, DD -1.2%
Other news: IMMU -45.6% (Belgium's UCB Phase 3 clinical trial program for Epratuzumab did not meet primary endpoint; Epratuzumab was licensed from IMMU), AMDA -30.3% (announced the FDA has requested co provide 24-month clinical performance data for pending 510(k) submission for the Valeo C Interbody with CsC Osteo-Conductive Scaffolding; co also provided in-line Q2 rev guidance), CARA -6.7% (commenced an underwritten public offering of shares of its common stock of up to $65 million), EGLT -5.4% (to offer and sell shares of its common stock in an underwritten public offering; size not disclosed), NYMX -1.6% (following 100% move higher yesterday), ADPT -1.5% (announces an offering of 2.75 mln shares of common stock; ~1.91 mln shares to be sold by co, ~843K shares to be sold by Sterling Partners shareholder group), YOKU -0.8% (following BIDU results), SINA -0.5% (following BIDU results)
Analyst comments: YELP -2.9% (downgraded to Hold from Buy at Deutsche Bank
)